Max Healthcare Institute Ltd Q1 FY23 Result Updates.
Robust growth in revenue & EBITDA driven by normalization of patient footfalls.

Max Healthcare reported a net profit of Rs. 229 crores, up by 12% YoY from Rs. 205 crores driven by annual price revision and normalisation of patient footfalls. Sequentially the net profit increased from Rs. 172 crores in the previous quarter.

Gross revenue stood at Rs. 1,473 Cr, a growth of 6% YoY and 14% QoQ .Net revenue increased to Rs. 1393 crores from Rs. 1322 crores in June 21, up by 5% YoY.Q1 FY23 performance reflects normalisation of revenues and operating EBITDA post Omicron wave in the previous quarter.
Max Healthcare stated that EBITDA stood at ₹370 crore compared to ₹360 crore in the corresponding quarter last year (Q1 FY22) and ₹304 crore in the previous quarter (Q4 FY22) growth of 3% YoY and 22% QoQ.

Improvement in all operational and financial parameters.

The Operating EBITDA margin stood at 26.6% for the quarter, compared to 25.3% in Q1 FY22 and 24.9% in Q4 FY22.
EBITDA per bed improved to Rs. 62.0 lakhs in Q1 FY23, from Rs. 45.4 lakhs in Q1 FY22 and Rs. 56.4 lakhs in Q4 FY22.
Bed occupancy in Q1 FY23 stood at 74%; 1% of total occupied beds were used for Covid‐19 patients compared to 7% in Q4 FY22 and 39% in Q1 FY 22.
Cash from Operations stood at Rs. 237 Cr in Q1 FY23.
Net Debt including Put Option liability of Rs. 141 Cr as on June 30, 2022 was Rs 217 Cr
Occupied Bed Days (‘OBD’) during the quarter increased by 9% over the previous quarter
Average revenue per occupied bed (ARPOB) for Q1 FY23 stood at Rs. 66.0k versus Rs. 51.5k in Q1 FY22 (+28% YoY) and Rs. 63.5k in Q4 FY22 (+4% QoQ)
Increase in ARPOB was led by improvement in payor mix and surgical mix, normalisation of OPD footfalls and annual price revision.
Digital revenue from online marketing activities and web-based appointments stood at INR 232 Cr, i.e. 16% of overall revenue.
Max Lab (Non-captive pathology vertical) reported gross revenue of Rs. 26 Cr.
Max@Home gross revenue during the quarter was INR 32 Cr, a growth of 10% over Q4 FY22 & 18% over Q1 FY22.
The growth in Q1 FY23 revenue and Operating EBITDA was driven mainly by improvement in payor mix, annual price revision and normalisation of patient footfalls after the Omicron wave waned in mid of Feb’22.

The shares of Max Healthcare are trading at Rs. 361, down by 2.94%.

Valuations:

The return on equity (ROE) is 10.3% for the quarter ended June 2022. The price-to-earning (P/E) ratio stood at 54.8. The return on capital employed (ROCE) for the company is 12.2%. The price to book value Max Healthcare is 5.54. The EV/EBITDA is 32.3. EPS for the quarter is Rs. 6.51.